Inactive Instrument

News Nightstar Therapeutics PLC

Stocks

US65413A1016

Biotechnology & Medical Research

All News

19-06-05	Nightstar Therapeutics plc Court Approval Received in Connection With Acquisition by Biogen	GL
19-05-29	Nightstar Therapeutics plc Update to Timetable Relating to the Acquisition by Biogen	GL
19-05-08	Nightstar Therapeutics PLC Shareholders Approve Scheme of Arrangement for Acquisition By Biogen at General Meeting and Court Meeting Held on 8 May 2019	GL
19-03-04	Nightstar Therapeutics plc reaches agreement to be acquired by Biogen	GL
18-11-13	Nightstar Announces Planned Initiation of Phase 2/3 Expansion Study in XIRIUS Trial for NSR-RPGR in XLRP and Reports Third Quarter 2018 Financial Results	GL
18-10-04	Nightstar Therapeutics to Present at Chardan Genetic Medicines Conference	GL
18-10-01	Nightstar Therapeutics to Present at 2018 Cell & Gene Meeting on the Mesa	GL
18-09-27	Nightstar Announces Pricing of Public Offering	GL
18-09-25	Nightstar Announces Proposed Public Offering of American Depositary Shares	GL
18-09-13	Nightstar Appoints Strategic Biotechnology Executive Paula Cobb to its Board of Directors	GL
18-08-13	Nightstar Therapeutics Reports Second Quarter 2018 Financial Results and Business Highlights	GL
18-08-07	Nightstar Therapeutics to Present at Wedbush PacGrow Healthcare Conference	GL
18-06-14	Nightstar Therapeutics : Receives Regenerative Medicine Advanced Therapy (RMAT) Designation for NSR-REP1 in Choroideremia	GL
18-06-14	Nightstar Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation for NSR-REP1 in Choroideremia	GL
18-06-06	Nightstar Therapeutics : Reports First Quarter 2018 Financial Results and Acceleration of Preliminary NSR-RPGR Readout to Third Quarter 2018	GL
18-05-31	Nightstar Therapeutics : to Present at Jefferies 2018 Global Healthcare Conference	GL
18-04-30	Nightstar Therapeutics : to Present at the Deutsche Bank 43rd Annual Health Care Conference	GL
18-04-23	Nightstar Therapeutics : to Present New Data in Choroideremia at the ARVO 2018 Annual Meeting	GL
18-04-03	Nightstar Therapeutics Reports 2017 Financial Results and Business Highlights	GL
18-03-05	Nightstar Therapeutics : Announces Initiation of STAR Phase 3 Registrational Trial for NSR-REP1 in Choroideremia	GL
17-12-07	Nightstar Therapeutics : to Participate in BMO Prescriptions for Success Healthcare Conference	GL
17-11-08	Nightstar Expands Pipeline with Novel Gene Therapy for the Treatment of Stargardt Disease	GL
17-10-30	Nightstar Therapeutics : to Participate in Multiple Conferences in November	GL
17-10-02	Nightstar Therapeutics : Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional American Depositary Shares	GL
17-10-02	Nightstar Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional American Depositary Shares	GL